Lipomeds

Lipomed is a privately owned Swiss life science company founded in 1993, specializing in the research, development, and manufacturing of ethical pharmaceuticals and active pharmaceutical ingredients (APIs). The company focuses on niche indications and rare diseases, particularly in the fields of hematology and oncology, with a portfolio that includes approved treatments like deferiprone and thalidomide. While its analytical reference standards business was acquired by LGC in 2021, Lipomed continues to operate as a pharmaceutical entity, recently partnering with Brenntag for the distribution of plant-based CBD API. The company maintains GMP/GDP certified production facilities in Arlesheim, Switzerland, and a subsidiary in Germany.